Researchers developed an electrochemical biosensor and AI system that accurately detects lung cancer from breath samples.
Key Details
- 1University of Texas at Dallas and UT Southwestern developed an electrochemical biosensor for breath analysis.
- 2The technology uses AI to analyze eight volatile organic compounds linked to thoracic cancers.
- 3In a study with 67 patients (30 biopsy-confirmed cancers), the device identified cancer-linked VOCs with 90% accuracy.
- 4The approach is designed for early, noninvasive, and affordable screening of lung and esophageal cancers.
- 5The technology was reported in the August issue of Sensing and Bio-Sensing Research.
Why It Matters
This innovation could enable routine, noninvasive, and cost-effective early detection of lung and other thoracic cancers, potentially improving survival rates and reducing burdens on healthcare systems. The integration of machine learning in biosensing highlights the expanding role of AI in clinical cancer diagnostics.
Source
EurekAlert
Related News
•EurekAlert
Mass General Brigham Spins Off AIwithCare to Transform Clinical Trial Screening
Mass General Brigham has spun out AIwithCare, a company commercializing RECTIFIER, an AI tool that automates and enhances clinical trial patient screening using EHR data.
•EurekAlert
AI-Driven CT Imaging Predicts Cardiac Events in Large UK Cohort
An AI tool analyzing CCTA images can predict future cardiovascular events and death in patients with suspected stable coronary artery disease.
•EurekAlert
AI Tool from UCLA Targets Undiagnosed Alzheimer's and Diagnostic Disparity
UCLA researchers developed an AI model using EHR data to better detect undiagnosed Alzheimer's disease, especially in underrepresented groups.